XML 72 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
License, Collaboration and Success Payment Agreements - Narrative (Details)
1 Months Ended 12 Months Ended
Oct. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
May 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
collaboration_target
Oct. 31, 2020
USD ($)
$ / shares
Jun. 30, 2020
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Reduction in net loss       $ (342,994,000) $ (234,632,000) $ (183,118,000)        
Reduction in net loss per common share, basic (in dollars per share) | $ / shares       $ (1.31) $ (0.93) $ (0.74)        
Reduction in net loss per common share, diluted (in dollars per share) | $ / shares       $ (1.31) $ (0.93) $ (0.74)        
Impairment of other investments       $ 13,001,000 $ 12,923,000 $ 5,000,000        
Gain on other investments       0 0 2,923,000        
PACT                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Impairment of other investments   $ 36,400,000                
Other Investment                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Impairment of other investments       13,000,000.0 12,900,000 5,000,000.0        
Series A Convertible Preferred Stock                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible preferred stock, par value (in dollars per share) | $ / shares               $ 1.83   $ 1.83
PACT                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Gain on other investments $ 2,900,000                  
PACT | Other Investment                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Impairment of other investments         2,900,000          
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Fred Hutch                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential aggregate success payments       0            
Term of success payment agreement                   9 years
Trigger period from IPO date                   1 year
Trigger period thereafter                   2 years
Fair value of potential success payments due       100,000 700,000          
Success payment expense/(gain)       (500,000) (1,900,000) (3,900,000)        
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Fred Hutch | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Multiple of initial equity value at issuance                   10
Potential aggregate success payments                   $ 10,000,000
Per share common stock price required for payment (in dollars per share) | $ / shares                   $ 18.29
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Fred Hutch | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Multiple of initial equity value at issuance                   50
Potential aggregate success payments                   $ 200,000,000
Per share common stock price required for payment (in dollars per share) | $ / shares                   $ 91.44
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Stanford                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential aggregate success payments       0            
Term of success payment agreement               9 years    
Trigger period from IPO date               1 year    
Trigger period thereafter               2 years    
Success payment expense/(gain)       (600,000) (900,000) (1,200,000)        
Annual license maintenance payments             $ 50,000      
Term of collaborative arrangement for research               4 years    
Aggregate research payments due               $ 12,000,000    
Research and development       2,300,000 3,000,000.0 3,000,000.0        
Success payment liability       300,000 900,000          
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Stanford | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Multiple of initial equity value at issuance               10    
Potential aggregate success payments               $ 10,000,000    
Per share common stock price required for payment (in dollars per share) | $ / shares               $ 18.29    
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Stanford | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Multiple of initial equity value at issuance               50    
Potential aggregate success payments               $ 200,000,000    
Per share common stock price required for payment (in dollars per share) | $ / shares               $ 91.44    
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | GSK                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Recognized revenue       0 $ 0 84,700,000        
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | GSK | Adjustment To Revenue Related To Change In Estimate                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Recognized revenue           83,600,000        
Reduction in net loss           $ 83,600,000        
Reduction in net loss per common share, basic (in dollars per share) | $ / shares         $ 0.34 $ 0.34        
Reduction in net loss per common share, diluted (in dollars per share) | $ / shares         $ 0.34 $ 0.34        
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | GSK | License                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Number of collaboration targets | collaboration_target             2      
Number of additional targets to nominate | collaboration_target             7      
Contract liabilities     $ 45,000,000 0            
Stock purchase agreement portion of transaction price     58,600,000              
Transaction price     $ 103,600,000              
Contract assets       $ 0            
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | GSK | Series AA Convertible Preferred Stock | License                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock sold under Stock Purchase Program (in shares) | shares     30,253,189              
Price per share of stock sold under Stock Purchase Program (in dollars per share) | $ / shares     $ 6.78              
Fair value per share of stock sold under Stock Purchase Program (in dollars per share) | $ / shares     $ 4.84              
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | PACT                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Strategic equity investment                 $ 36,400,000